Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

129.23 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,259
Open 129.23
Bid (Size) 131.85 (2)
Ask (Size) 131.93 (2)
Prev. Close 129.23
Today's Range 129.23 - 129.23
52wk Range 78.19 - 148.15
Shares Outstanding N/A
Dividend Yield 1.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
FDA reports hospitalizations due to overdoses from compounded semaglutide products. Patients and health care providers miscalculate doses, leading to serious adverse events. The FDA advises proper... 
Via Benzinga
Exposures Product Safety
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Liraglutide shows promise in slowing cognitive decline in Alzheimer's patients, reducing brain volume loss and offering neuroprotective benefits, according to a Phase 2b clinical trial presented at... 
Via Benzinga

Performance

YTD
+26.56%
+26.56%
1 Month
-11.13%
-11.13%
3 Month
+0.72%
+0.72%
6 Month
+18.54%
+18.54%
1 Year
+60.43%
+60.43%

More News

Read More
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
Via Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Via Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Via The Motley Fool
Novo Nordisk Unusual Options Activity For July 26
Via Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
3 Overlooked Stocks Poised for a Breakout Very Soon
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
This Could Send Ozempic's Sales Potential to a Whole Other Level
Via The Motley Fool
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Via Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Via Benzinga
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Via Investor's Business Daily
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
Beware, Wegovy -- Pfizer Is Working on a Competitor
Via The Motley Fool
3 Fabulous Growth Stocks to Buy and Hold Forever
Via InvestorPlace
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Via Benzinga
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.